There was no significant difference in the risk of hypersensitivity reactions with low-dose or high-dose dexamethasone.
Next-generation sequencing provided actionable information for patients with uterine cancer.
Avelumab did not improve progression-free survival when given concurrently with chemotherapy or as maintenance.
Most adverse events in the olaparib arm were manageable with supportive treatment or dose modifications.
PARP inhibitor use increased regardless of BRCA mutation status.